WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has recently experienced a daily loss of 2.19% and a 3-month loss of 10.22%. The company's Earnings Per Share (EPS) (EPS) also indicate a loss of 2.32.

Deciphera Pharmaceuticals is set to be acquired in a $2.4bn buyout, as the biopharma announced that it has commenced a definitive merger agreement with ONO Pharmaceutical. Under the terms of the ...

Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...

A devastating trial flop for Deciphera's gastrointestinal cancer drug Qinlock has prompted the company to undergo a painful transformation. On Tuesday, the Massachusetts biopharma said it will cut 140 ...

- Data Featured at the ESMO World Congress on Gastrointestinal Cancer 2020 Virtual Meeting - “The data presented today further reinforce the potential of QINLOCK to provide meaningful clinical benefit ...

In less than 24 hours, the FDA handed out one rejection and one thumbs-up to two rival drugs for a rare stomach cancer. On the heels of turning down Blueprint Medicines’ Ayvakit as a therapy for ...